The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRVN | -99.45% | -100% | -90.61% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +281% |
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
These high-risk, high-reward healthcare stocks have outperformed the market over the past year.
This is the story of an emerging healthcare company on its way to capturing a billion-dollar market opportunity.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.28M | 0.0% |
| Gross Profit | $0.07M | 0.0% |
| Gross Margin | 26.15% | 0.0% |
| Market Cap | $3.19M | 0.0% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 23 | 0.0% |
| Net Income | -$4.94M | 0.0% |
| EBITDA | -$5.48M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $13.74M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.56M | 0.0% |
| Short Term Debt | $2.00M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -105.78% | 0.0% |
| Return On Invested Capital | -93.32% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.50M | 0.0% |
| Operating Free Cash Flow | -$4.50M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.00 | -1.04 | -0.27 | -0.17 | - |
| Price to Sales | 3.61 | 3.12 | 10.47 | 5.83 | - |
| Price to Tangible Book Value | 3.00 | -1.04 | -0.27 | -0.17 | - |
| Enterprise Value to EBITDA | -1.47 | -2.32 | -3.86 | -4.93 | - |
| Return on Equity | -1014.1% | - | |||
| Total Debt | $36.25M | $36.51M | $36.47M | $37.56M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
